James R. Patrinely

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “A multicenter characterization of hepatitis associated with immune checkpoint inhibitors”.

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

OncoImmunology(2021)10.1080/2162402x.2021.1875639

N/A

2.2DataRank · unranked

63 citations

Ben McGuigan, Sunandana Chandra, Sarah E. Fenton, Akansha Chowdhary, Lucy Boyce Kennedy +14 more

Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9591

N/A

0.292DataRank · unranked

6 citations

Aleigha Lawless, Rachel Woodford, Faisal Fa’ak, Asha Tipirneni, James R. Patrinely +11 more

Outcomes after progression of disease with anti–PD‐1/PD‐L1 therapy for patients with advanced melanoma

Cancer(2020)10.1002/cncr.32984

N/A

0DataRank · unranked

40 citations

Laura X. Baker, Elizabeth J. Davis, Haocan Song, Fei Ye, Douglas B. Johnson +1 more

The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer

BioDrugs(2020)10.1007/s40259-020-00428-9

N/A

0DataRank · unranked

25 citations

Anna K. Dewan, Douglas B. Johnson, James R. Patrinely

A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis

The Oncologist(2020)10.1002/onco.13608

N/A

0DataRank · unranked

4 citations

Elisa Funck‐Brentano, Khang Nguyen, Suthee Rapisuwon, Joe‐Elie Salem, Geoffrey T. Gibney +3 more

Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research

The Lancet Oncology(2020)10.1016/s1470-2045(20)30107-8

N/A

0DataRank · unranked

110 citations

Kerry L. Reynolds, Ryan J. Sullivan, Justin M. Balko, James R. Patrinely, Laura C. Cappelli +3 more

The modern dermatology program director: A cross-sectional study on personal and professional characteristics

Journal of the American Academy of Dermatology(2020)10.1016/j.jaad.2020.05.140

N/A

0DataRank · unranked

0 citations

Anna K. Dewan, James R. Patrinely

Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

JAMA Oncology(2021)10.1001/jamaoncol.2021.0051

N/A

0DataRank · unranked

254 citations

Rebecca Johnson, Aleigha Lawless, Prachi Bhave, Amelia Sawyers, Maya Dimitrova +15 more

Characterizing toxicities, body composition, and health-related quality of life (HRQoL) among long-term survivors treated with anti-PD-1.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e15158

N/A

0DataRank · unranked

0 citations

Arissa Young, Henry T. Quach, Grant R. Williams, Fei Ye, Run Fan +8 more

Individual cell motion in healthy human skin microvasculature by reflectance confocal video microscopy

Microcirculation(2020)10.1111/micc.12621

N/A

0DataRank · unranked

19 citations

Zijun Zhao, James R. Patrinely, Michael Byrne, Madan Jagasia, Eric R. Tkaczyk +1 more